These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1174 related articles for article (PubMed ID: 2503541)
1. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA. Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541 [TBL] [Abstract][Full Text] [Related]
2. Plasminogen activator inhibitor 1 contains a cryptic high affinity receptor binding site that is exposed upon complex formation with tissue-type plasminogen activator. Horn IR; van den Berg BM; Moestrup SK; Pannekoek H; van Zonneveld AJ Thromb Haemost; 1998 Nov; 80(5):822-8. PubMed ID: 9843178 [TBL] [Abstract][Full Text] [Related]
3. Characterization of domain deletion and/or duplication mutants of a recombinant chimera of tissue-type plasminogen activator and urokinase-type plasminogen activator (rt-PA/u-PA). Nelles L; Lijnen HR; Van Nuffelen A; Demarsin E; Collen D Thromb Haemost; 1990 Aug; 64(1):53-60. PubMed ID: 2148847 [TBL] [Abstract][Full Text] [Related]
4. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site. Colucci M; Cavallo LG; Agnelli G; Mele A; Bürgi R; Heim J; Semeraro N Thromb Haemost; 1993 May; 69(5):466-72. PubMed ID: 8391727 [TBL] [Abstract][Full Text] [Related]
5. Depression of tissue-type plasminogen activator and enhancement of urokinase-type plasminogen activator as an expression of local inflammation. Brommer EJ; Dooijewaard G; Dijkmans BA; Breedveld FC Thromb Haemost; 1992 Aug; 68(2):180-4. PubMed ID: 1412164 [TBL] [Abstract][Full Text] [Related]
6. Fibrin induction of tissue plasminogen activator expression in corneal endothelial cells in vitro. Ramsby ML; Kreutzer DL Invest Ophthalmol Vis Sci; 1993 Oct; 34(11):3207-19. PubMed ID: 7691778 [TBL] [Abstract][Full Text] [Related]
7. Structure and function of human tissue-type plasminogen activator (t-PA). van Zonneveld AJ; Veerman H; MacDonald ME; van Mourik JA; Pannekoek H J Cell Biochem; 1986; 32(3):169-78. PubMed ID: 3097031 [TBL] [Abstract][Full Text] [Related]
9. Cellular degradation of free and inhibitor-bound tissue-type plasminogen activator--requirement for a co-receptor? Camani C; Gavin O; Kruithof EK Thromb Haemost; 2000 Feb; 83(2):290-6. PubMed ID: 10739388 [TBL] [Abstract][Full Text] [Related]
10. Plasminogen-dependent and -independent proteolytic activity of murine endothelioma cells with targeted inactivation of fibrinolytic genes. Lijnen HR; Wagner EF; Collen D Thromb Haemost; 1997 Feb; 77(2):362-7. PubMed ID: 9157597 [TBL] [Abstract][Full Text] [Related]
11. The interaction of plasminogen activator inhibitor 1 with plasminogen activators (tissue-type and urokinase-type) and fibrin: localization of interaction sites and physiologic relevance. Keijer J; Linders M; van Zonneveld AJ; Ehrlich HJ; de Boer JP; Pannekoek H Blood; 1991 Jul; 78(2):401-9. PubMed ID: 1712649 [TBL] [Abstract][Full Text] [Related]
12. Endotoxin-induced intravascular coagulation in rabbits: effect of tissue plasminogen activator vs urokinase of PAI generation, fibrin deposits and mortality. Paloma MJ; Páramo JA; Rocha E Thromb Haemost; 1995 Dec; 74(6):1578-82. PubMed ID: 8772240 [TBL] [Abstract][Full Text] [Related]
13. Biological effects of combined inactivation of plasminogen activator and plasminogen activator inhibitor-1 gene function in mice. Lijnen HR; Moons L; Beelen V; Carmelie P; Collen D Thromb Haemost; 1995 Oct; 74(4):1126-31. PubMed ID: 8560424 [TBL] [Abstract][Full Text] [Related]
14. Plasminogen activator inhibitors type 1 and type 2 and plasminogen activators in amniotic fluid during pregnancy. Estellés A; Gilabert J; Andrés C; España F; Aznar J Thromb Haemost; 1990 Oct; 64(2):281-5. PubMed ID: 2125378 [TBL] [Abstract][Full Text] [Related]
15. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro. Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946 [TBL] [Abstract][Full Text] [Related]
16. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes. Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392 [TBL] [Abstract][Full Text] [Related]
17. Monocyte plasminogen activator inhibitor 2 (PAI-2) inhibits u-PA-mediated fibrin clot lysis and is cross-linked to fibrin. Ritchie H; Robbie LA; Kinghorn S; Exley R; Booth NA Thromb Haemost; 1999 Jan; 81(1):96-103. PubMed ID: 10348718 [TBL] [Abstract][Full Text] [Related]
18. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways. Munkvad S Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763 [TBL] [Abstract][Full Text] [Related]
19. Modulation of urokinase-type plasminogen activator and plasminogen activator inhibitor-2 expression by U-937 mononuclear phagocytes. Effects of 1 alpha, 25-dihydroxyvitamin D3 and phorbol ester. Gyetko MR; Webb AC; Sitrin RG J Immunol; 1988 Oct; 141(8):2693-8. PubMed ID: 3139763 [TBL] [Abstract][Full Text] [Related]
20. Expression of plasminogen activators and plasminogen activator inhibitor 1 in dedifferentiated chondrosarcoma. Häckel C; Czerniak B; Ayala AG; Radig K; Roessner A Cancer; 1997 Jan; 79(1):53-8. PubMed ID: 8988726 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]